

Company announcement no 12/2022

Interim Report Q2 2022

EBITDA fixed herd prices (FHP) for Q2 2022 decreased to 5,733 mEUR (Q2 2021: 6,111 kEUR), corresponding to an EBITDA margin FHP of 22.1% (Q2 2021: 21.6%). The quarterly EBITDA decreased by 378 kEUR (compared to Q2 2021), but the relatively small change has several significant effects. On the positive side, subsidy in LT of 2.530 kEUR and improved sales prices in LT of 3.104 kEUR, nevertheless increasing feed prices, lower sales prices in Russia, higher production cost combined with Ostrov site only partly in operation are higher than the positive effects.

Sales prices in Q2 were 1.31 EUR/kg live weight, up from 1,20 EUR/kg (Q2 2021). Better prices have been driven by the price increase in LT, which increased by 0,24 EUR/kg compared to 2021.

Feed prices in Q2 2022 were 282 EUR/T (compared to 238 EUR/T Q2 2021), and the price increased on key feed components and dramatical on some (e.g., premix and proteins). The feed prices reflect that grain prices in LT were fixed.

Grain prices have changed during Q2 from an upwards trend to a downwards. Idavang decided to exit the matif (hedges in LT) over an extended period. Mid-July did Idavang close the last hedge position for the new harvest. Hence the price is now fully variable for Lithuania. End June Idavang had received 6,4 mEUR for the closed matif positions and an additional 0,4 mEUR in July (other receivables with 0,6 mEUR in Q2 report).

Idavang EBITDA (FHP) will the next year be highly impacted by the 8,6 mEUR matif gains already exercised, and included in equity and cash position. Hence, if current production cost is calculated without all matif gains and favorable hedges, then the Lithuanian cash EBITDA production price is estimated to be 1,33-1,35 EUR/kg, without subsidies.

Subsidy for high feed prices received in LT of 2,5 mEUR in Q2, and an additional 2,5 mEUR is expected in Q3.

The herd valuation in Q2 decreased by 2,247 kEUR (compared to 31.03.2022). The decrease is mainly due to reducing prices of 30 kg. Free cash flow was 11,059 kEUR in Q2 2021 (Q2 2021: 4,735 kEUR). Net interest-bearing debt has decreased from 78,5 mEUR (31.12.2021) to 71,9 mEUR driven by the closed matif contracts 6,4 mEUR.

Lack of exchangeability EURRUB

EURRUB for the period April-June has in the report been included with 93,70 equals to FX used on 31/3 in Q1 report. Current status is that RUB cannot be exchanged to EUR and transfers out of Russia is also not possible.

EURRUB FX exchange made public by the Russian central bank here has limited actual use and ECB stopped publishing FX rates on RUB on 1st Marts 2022 (EURRUB 117,20). Therefore, Idavang expects to apply Exposure Draft from IFRS on Lack of exchangeability if EURRUB does not get normally exchangeable before.

Selected financial highlights and key ratios

EUR millions	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Total revenue	25.957	28.305	46.528	53.065	100.163
EBITDA	3.486	3.667	10.934	15.157	14.629
EBITDA margin	13,4%	13,0%	23,5%	28,6%	14,6%
EBITDA fixed herd price	5.733	6.111	5.996	7.861	14.358
EBITDA margin fixed herd price	22,1%	21,6%	12,9%	14,8%	14,3%
Net income	901	543	4.408	7.945	2.413
Free cash flow	11.059	4.735	7.407	7.263	16.033
Net interest-bearing debt	71.867	84.251	71.867	84.251	78.455

Further information

Bondholders - Claus Baltersen, CEO phone +370 (685) 34 104

Media - Jytte Rosenmaj, Board Member phone +45 26 73 46 99

Finance Calendar 2021

30th November 2022: Q2 Interim report 2022

28th February 2023: Annual report 2022

Forward-looking statements

This interim report contains “forward-looking statements.” Undue reliance should not be placed on forward-looking statements because they relate to and depend on circumstances that may or may not occur in the future, and actual results may differ materially from those in forward-looking statements. Forward-looking statements include, without limitation, statements regarding our business, financial circumstances, strategy, results of operations, financing and other plans, objectives, assumptions, expectations, prospects, beliefs and other future events and prospects. We undertake no obligation and do not intend to publicly update or revise any of these forward-looking statements unless prescribed by law or by stock exchange regulation.

Table of contents

REVIEW	4
Financial Highlights and Key Ratios.....	4
Management's Review	5
Development in segments in Q2 2022	6
Statement by the Board and the Executive Management.....	8
FINANCIAL STATEMENT	9
Income Statement	9
Statement of comprehensive income	9
Assets	10
Liabilities and Equity.....	10
Cash Flow Statement	11
Statement of changes in equity	12
Notes.....	13
Quarterly Financial Highlights and Key Ratios.....	18

Review

Financial Highlights and Key Ratios

EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Income statement					
Revenue	25.957	28.305	46.528	53.065	100.163
EBITDA	3.486	3.667	10.934	15.157	14.629
EBITDA fixed herd price	5.733	6.111	5.996	7.861	14.358
EBIT	1.936	1.836	7.683	11.555	7.497
Financial items, net	-449	-1.285	-2.071	-2.718	-5.469
Profit/(loss) for the period	901	543	4.408	7.945	2.413
Cash flow					
Operating activity	11.956	5.136	8.785	5.696	11.396
Investing activity	-1.084	-1.686	-3.239	-1.616	-1.122
Financing activity	-8.437	-2.446	-10.634	-6.508	-11.230
Free cash flow	11.059	4.735	7.407	7.263	16.033
Balance sheet					
Non-current assets	88.841	96.811	88.841	96.811	93.926
Net working capital	29.025	32.364	29.025	32.364	26.866
Net operating assets	117.866	129.175	117.866	129.175	120.792
Total assets	138.172	155.033	138.172	155.033	146.166
Equity	42.860	41.065	42.860	41.065	39.744
Net interest bearing debt	71.867	84.251	71.867	84.251	78.455
Key financials Group					
EBITDA margin	13,4%	13,0%	23,5%	28,6%	14,6%
EBITDA margin - fixed herd prices	22,1%	21,6%	12,9%	14,8%	14,3%
Cash conversion - fixed herd prices	193%	77%	124%	92%	112%
NIBD / EBITDA fixed price LTM	5,8	5,4	5,8	5,4	5,5
Equity ratio	31,0%	26,5%	31,0%	26,5%	27,2%

Management's Review

Income statement

Revenue

The revenue for Q2 2022 was 25,957 kEUR (Q2 2021: 28,305 kEUR) down 8%. The lower sale split into higher sales prices (in Lithuania) and lower volume in Russia (missing Ostrov volume).

Value adjustment, biological assets

The herd valuation in Q2 decreased by 2,247 kEUR (compared to 31.03.2021). The decrease is mainly due to reducing prices of 30 kg.

EBITDA fixed herd prices (FHP)

EBITDA fixed herd prices (FHP) for Q2 2022 decreased to 5,733 mEUR (Q2 2021: 6,111 kEUR), corresponding to an EBITDA margin FHP of 22.1% (Q2 2021: 21.6%). The quarterly EBITDA decreased by 378 kEUR (compared to Q2 2021), but the relatively small change has several significant effects. On the positive side, subsidy in LT of 2.530 kEUR and improved sales prices in LT of 3.104 kEUR, nevertheless increasing feed lower sales prices in Russia and production cost combined with Ostrov site not operating are higher.

Sales prices in Q2 were 1.31 EUR/kg live weight, up from 1,20 EUR/kg (Q2 2021). Better prices have been driven by the price increase in LT, which increased by 0,24 EUR/kg compared to 2021.

Feed prices in Q2 2022 were 282 EUR/T (compared to 238 EUR/T Q2 2021), and the price increased on key feed components and dramatical on some (e.g., premix and proteins). The feed prices reflect that grain prices in LT were fixed.

Net financials

The net interest expenses for Q2 2022 decreased 1,349 kEUR to 187 kEUR (Q2 2021: 1,536 kEUR), mainly related to gains on purchased own bonds during Q2. Foreign exchange adjustments in Q2 2022 were negative with 262 kEUR (Q1 2021 +251 kEUR).

Balance Sheet

At 30th June 2022, Idavang's balance sheet amounted to 138,172 kEUR (December 2021: 146,166 kEUR). Equity on 30th June 2022 amounted to EUR 42.9m at an equity ratio of 31,0%. Net interest-bearing debt has decreased from 78,5 mEUR (31.12.2021) to 71,9 mEUR driven by the closed matif contracts 6,4 mEUR.

The networking capital increased to 29,025 kEUR (from 26,860 kEUR 31.12.2021). The increase of 2,1 mEUR is a decrease if adjusted for 4,9 mEUR herd value adjustment and this is due to matif contracts have been converted into cash.

Cash flow

Cash flow from ordinary activities for Q2 2022 increased to 11.956 kEUR (Q2 2021: 5.136 kEUR).

The increase of 6,820 kEUR is mainly due to two effects. The first a positive impact on Q2 2022 of matif contracts converted into cash, hence decrease of other receivables with 3,0 mEUR compared to Q1 2022, and the second is a negative in Q2 2021 where factoring was stopped consequently trade receivables reduced 2,4 mEUR combined the are 5,4 mEUR of the improvement.

Situation in Russia

Idavang has as earlier stated isolated the activities in Russia. Hence, money is not transferred from Denmark to Russia or vice versa. All investments in Russia are stopped.

Idavang follows the situation closely to secure that the company continues to be in compliance with all Danish and EU sanctions towards Russia. If Russia's current status in the world is not significant improved, it is estimated that it will be very difficult to operate in Russia. Results will be negative influenced due to supplies, market conditions, political factors etc

From an economic point of view the production in Russia is approximate half of the Groups activity, and a significant part of the security towards the listed bond.

Events after the balance sheet date

- No events after the balance sheet date

Development in segments in Q2 2022

Lithuania

EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Revenue	19.148	15.386	32.492	28.452	53.864
Value adjustment, biological assets	-1.123	-1.648	4.250	5.070	159
Production costs	-16.470	-13.688	-30.807	-27.230	-56.338
Administrative costs	-543	-454	-1.051	-891	-1.808
Other income	3.174	410	3.468	641	2.818
Other expense	6	188	12	322	-
Operating profit	4.192	195	8.365	6.363	-1.305
Net Financials	-239	-307	-559	-604	-969
Foreign exchange adjustments	-	-	-	-	14
Profit before tax	3.953	-112	7.807	5.759	-2.260
Tax on profit for the year	-597	17	-1.178	-867	492
Profit for the period	3.355	-95	6.628	4.891	-1.768



EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Depreciations included in production cost	-657	-732	-1.313	-1.483	-2.905
EBITDA	4.849	927	9.678	7.846	1.600
<i>EBITDA fixed herd prices</i>	<i>5.972</i>	<i>2.575</i>	<i>5.428</i>	<i>2.776</i>	<i>1.441</i>

Lithuania accounted for 74 % of Group revenue in Q2 2022 (Q2 2021: 54 %).

The EBITDA fixed herd price for Q2 2021 amounted to 5,972 kEUR, corresponding to an EBITDA margin of 31.2% (Q2 2021: 2,575 kEUR and EBITDA margin 16.7%). The EBITDA increased compared to Q2 2021 by 3.397 kEUR, mainly explained by the subsidy received in Q2 2022 of 2.530 kEUR, positive sales price effect of 3.104 kEUR, and negative cost effect, especially from feed (1.821 kEUR).

The sales price increased 21 % compared to Q2 2021 to an average of 1,38 EUR per kilo slaughter pigs' live weight in Q2 2022 (Q2 2021: 1,14 EUR per kilo live weight slaughter pigs) with 3.104 kEUR positive effect.

Idavang EBITDA (FHP) will the next year be highly impacted by the 8,6 mEUR matif gains already exercised, and included in equity and cash position. Hence, if current production cost is calculated without all matif gains and favorable hedges, then the Lithuanian cash EBITDA production price is estimated to be 1,33-1,35 EUR/kg, without subsidies.



Russia



EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Revenue	6.809	12.919	14.036	24.613	46.298
Value adjustment, biological assets	-1.124	-797	688	2.226	112
Production costs	-7.677	-10.224	-14.913	-21.028	-42.010
Administrative costs	-261	-303	-509	-585	-1.287
Other income	99	147	252	234	6.865
Other expense	-	-	-	-	-551
Operating profit	-2.154	1.741	-446	5.460	9.428
Net Financials	-191	-330	-455	-662	-1.203
Foreign exchange adjustments	-273	5	109	-34	-209
Profit before tax	-2.618	1.416	-792	4.764	8.016
Tax on profit for the year	11	-24	-26	-24	-107
Profit for the period	-2.607	1.392	-818	4.740	7.909

EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Depreciations included in production cost	-892	-1.098	-1.938	-2.120	-4.227
EBITDA	-1.262	2.840	1.492	7.580	13.655
<i>EBITDA fixed herd prices</i>	<i>-138</i>	<i>3.637</i>	<i>804</i>	<i>5.354</i>	<i>13.544</i>

Russia accounted for 26 % of Group revenue in Q2 2022 (Q2 2021: 46 %).

The EBITDA fixed herd price for Q2 2021 amounted to -138 kEUR, corresponding to a negative EBITDA margin (Q2 2021: 3,637 kEUR and EBITDA margin 28.2 %) an increase of 3,775 kEUR. The EBITDA decreased is roughly half due to sales/feed prices and half due to lack of Ostrov operation.

The sales price decreased 10 % compared to Q2 2021 to an average of 1,14 EUR per kilo slaughter pigs' live weight in Q2 2022 (Q2 2021: 1,27 EUR per kilo live weight slaughter pigs) with 773 kEUR negative effect.



Statement by the Board and the Executive Management

The Executive Board and the Board of Directors have presented the interim Report of Idavang A/S. The interim report has today been considered and adopted.

The Interim Report, which has not been audited or reviewed by the Company's independent auditors, was prepared in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU and additional Danish disclosure requirements for listed companies.

In our opinion, the Interim Financial Statements give a true and fair view of the financial position of the Group at 30th June 2022 as well as of the results of the Group operations and cash flows for the period 1st Jan – 30th June 2022.

In our opinion, Management's Review gives a true and fair account of the development in the activities and financial circumstances of the Group, of results of operations for the period and of the overall financial position of the Group, and a description of the key risks and uncertainties facing the Group.

Executive Management

Claus Baltzersern
CEO



Michael Thuesen Henriksen
CFO



Board of Directors



Niels Hermansen
Chairman



Jytte Rosenmaj



Carsten Lund Thomsen



Claus Baltzersen



Ole B. Hansen

Financial Statement

Income Statement

EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Revenue	25.957	28.305	46.528	53.065	100.163
Value adjustment, biological assets	-2.247	-2.445	4.938	7.296	271
Production costs	-24.147	-23.912	-45.720	-48.258	-98.348
Administrative costs	-913	-858	-1.796	-1.745	-3.721
Other income	3.273	557	3.720	875	9.683
Other expense	13	188	12	322	-551
Operating profit	1.936	1.836	7.683	11.555	7.497
Net Financials	-187	-1.536	-1.861	-3.184	-5.991
Foreign exchange adjustments	-262	251	-210	466	522
Profit before tax	1.487	551	5.612	8.837	2.028
Tax on profit for the year	-586	-8	-1.204	-892	385
Profit for the period	901	543	4.408	7.945	2.413

EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Depreciations included in production cost	-1.550	-1.830	-3.251	-3.602	-7.132
EBITDA	3.486	3.667	10.934	15.157	14.629
<i>EBITDA fixed herd prices</i>	<i>5.733</i>	<i>6.111</i>	<i>5.996</i>	<i>7.861</i>	<i>14.358</i>

Statement of comprehensive income

EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Profit for the period	901	543	4.408	7.945	2.413
Other comprehensive income					
Exchange adjustments, foreign subsidiaries	35	1.330	-5.655	2.242	3.737
Hedge accounting	1.961	961	4.363	1.011	3.726
Other comprehensive income to be reclassified to profit or loss in subsequent periods	1.996	2.291	-1.292	3.253	7.463
Other comprehensive income not to be reclassified to profit or loss in subsequent periods	-	-	-	-	-
Total comprehensive income	2.896	2.834	3.116	11.197	9.876

Assets

EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Intangible assets	1.196	1.232	1.196	1.232	1.222
Property, Plant and Equipment	73.331	79.814	73.331	79.814	79.404
Biological Assets, Breeding herd	13.108	14.554	13.108	14.554	12.094
Deferred tax	761	760	761	760	761
Financial fixed assets	445	451	445	451	446
Total non-current assets	88.841	96.811	88.841	96.811	93.926
Inventories	11.472	10.134	11.472	10.134	15.007
Biological Assets, Commercial herd	19.423	25.493	19.423	25.493	14.889
Biological Assets, Arable	2.536	3.053	2.536	3.053	1.004
Biological Assets	21.959	28.546	21.959	28.546	15.892
Trade receivables	5.282	5.334	5.282	5.334	4.404
Other receivables	1.900	1.205	1.900	1.205	494
Prepayments	663	1.225	663	1.225	2.280
Income taxes receivables	390	-	390	-	618
Receivables	8.234	7.764	8.234	7.764	7.796
Assets held for sale	-	-	-	-	-
Cash	7.665	11.777	7.665	11.777	13.545
Total current assets	49.331	58.222	49.331	58.222	52.240
Total Assets	138.172	155.033	138.172	155.033	146.166

Liabilities and Equity

EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Share capital	800	800	800	800	800
Exchange adjustments	-40.495	-36.335	-40.495	-36.335	-34.840
Other reserves	8.636	1.558	8.636	1.558	4.273
Retained earnings	73.919	75.043	73.919	75.043	69.511
Equity	42.860	41.065	42.860	41.065	39.744
Borrowings	66.135	74.070	66.135	74.070	74.157
Grants	1.472	1.581	1.472	1.581	1.563
Deferred tax	1.666	2.279	1.666	2.279	1.029
Provisions	-	-	-	-	-
Other non-current liabilities	654	39	654	39	760
Non current liabilities	69.927	77.968	69.927	77.968	77.509
Borrowings	13.398	21.958	13.398	21.958	17.844
Trade payables	8.887	8.795	8.887	8.795	7.937
Income taxes payables	272	1.027	272	1.027	-
Other payables	2.828	4.219	2.828	4.219	3.132
Current liabilities	25.385	36.000	25.385	36.000	28.913
Total liabilities	95.312	113.968	95.312	113.968	106.422
Total Equity and Liabilities	138.172	155.033	138.172	155.033	146.166

Cash Flow Statement

EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2.021
Operating profit/loss	1.936	1.836	7.683	11.555	7.497
Adjustment for non-cash operating items	8.989	5.236	2.107	- 2.682	10.384
	10.925	7.072	9.790	8.872	17.881
Change in working capital incl. herd	1.249	- 778	1.029	- 329	558
Cash flow from ordinary activities before financials	12.174	6.294	10.818	8.544	18.439
Net financials	- 187	- 1.285	- 1.861	- 3.184	- 5.759
Corporate tax paid	- 31	127	- 173	336	- 1.284
Cash flow from ordinary activities	11.956	5.136	8.785	5.696	11.396
Cash flow from investing activities	- 1.084	- 1.686	- 3.239	- 1.616	- 1.122
Proceeds from borrowings	1.601	6.202	1.601	9.206	13.066
Repayments of borrowings	- 10.038	- 8.648	- 12.235	- 15.714	- 24.296
Dividends paid to shareholders	-	-	-	-	-
Surplus on Escrow account	-	-	-	-	-
Cash flow from financing activities	- 8.437	- 2.446	- 10.634	- 6.508	- 11.230
Cash and cash equivalents primo priod	5.489	10.364	13.545	13.757	13.757
Change in cash and cash equivalents	2.435	1.004	- 5.088	- 2.429	- 956
Exchange adjustments	- 259	409	- 792	449	744
Cash and cash equivalents end priod	7.665	11.777	7.665	11.777	13.545

The group has 8.955 kEUR overdraft facilities not utilized at period-end and owns 8.200 kEUR Idavang Bonds.

Financial position split in detail as of 30.06.2022

kEUR	Cash	Debt	Not utilized overdraft
RU	3.127	12.306	455
DK/LT	4.539	67.226	8.500
Total	7.665	79.533	8.955

Statement of changes in equity

EUR '000	Share capital	Exchange adjustment	Other reserves	Retained earnings	Total
Equity at 1st January 2022	800	- 34.840	4.273	69.511	39.744
Profit/Loss for the period				4.408	4.408
Other comprehensive income		- 5.655	4.363		- 1.292
Total comprehensive income	-	- 5.655	4.363	4.408	3.116
Equity at 30th June 2022	800	- 40.495	8.636	73.919	42.860

EUR '000	Share capital	Exchange adjustment	Other reserves	Retained earnings	Total
Equity at 1st January 2021	800	- 38.577	547	67.098	29.868
Profit/Loss for the period				2.413	2.413
Other comprehensive income		3.737	3.726		7.463
Total comprehensive income	-	3.737	3.726	2.413	9.876
Dividend					-
Repurchase shares					
Equity at 31st December 2021	800	- 34.840	4.273	69.511	39.744

Notes

Note 1 Basis of preparation and changes to the Group's accounting policies

The interim condensed consolidated financial statements for the 6 months ended 30th Jun 2021 have been prepared in accordance with Idavang A/S' accounting policies as stated in the latest financial statements for the company and in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU and additional Danish disclosure requirements for interim financial reporting of listed companies.

The consolidated financial statements are presented in thousand EUR.

The Interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as at 31st Dec 2021.

The Group's accounting policies is unchanged compared with the Group's annual financial statements as at 31st Dec 2021.

Note 2 Biological assets measured at fair value

The change in the value of biological assets for Q2 2022 is stated in the below table. The total change in fair value is included in revenue reported in the income statement.

EUR '000	Q2 2022	Q2 2021	6M 2022	6M 2021	2021
Commercial herd primo	20.989	27.458	14.889	17.116	17.116
Change in fair value	-981	-1.831	5.715	8.305	-2.772
Exchange adjustments	-585	-134	-1.180	72	545
Commercial herd ultimo	19.423	25.493	19.423	25.493	14.889
Breeding herd primo	12.699	14.490	12.094	15.469	15.469
Change in fair value	2.027	-105	2.525	-1.218	-3.780
Exchange adjustments	-1.617	169	-1.510	304	405
Breeding herd ultimo	13.108	14.554	13.108	14.554	12.094
Herd total primo	33.688	41.948	26.982	32.585	32.585
Change in fair value due to volume	3.294	509	3.302	-209	-6.824
Change in fair value due to price	-2.247	-2.445	4.938	7.296	271
Exchange adjustments	-2.203	35	-2.691	376	950
Herd total ultimo	32.532	40.048	32.532	40.048	26.982
Crop primo	1.372	1.607	1.004	1.099	1.099
Change in fair value due to volume	1.328	1.549	1.858	2.026	-175
Change in fair value due to price	-	-	-	-	-
Exchange adjustments	-163	-102	-326	-72	80
Crop ultimo	2.536	3.053	2.536	3.053	1.004
Total Biological Assets primo	35.059	43.555	27.986	33.684	33.684
Change in fair value due to volume	4.621	2.057	5.160	1.817	-6.999
Change in fair value due to price	-2.247	-2.445	4.938	7.296	271
Exchange adjustments	-2.366	-67	-3.017	304	1.030
Total Biological Assets ultimo	35.068	43.101	35.068	43.100	27.986

Note 3 Segment reporting

The group's results break down as follows on segments:

Q2 2022				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	19.148	6.809	-	25.957
Value adjustment, biological assets	- 1.123	- 1.124	-	- 2.247
Production costs	- 16.470	- 7.677	-	- 24.147
Administrative costs	- 543	- 261	- 109	- 913
Other income	3.174	99	-	3.273
Other expense	6	-	7	13
Operating profit	4.192	2.154	102	1.936
Net Financials	- 239	- 191	243	- 187
Foreign exchange adjustments	-	- 273	11	- 262
Profit before tax	3.953	2.618	152	1.487
Tax on profit for the year	- 597	11	-	- 586
Profit for the period	3.355	2.607	152	901
EUR '000				
Depreciations included in production cost	- 657	- 892	-	- 1.550
EBITDA	4.849	1.262	102	3.486
<i>EBITDA fixed herd prices</i>	<i>5.972</i>	<i>138</i>	<i>102</i>	<i>5.733</i>
Q2 2021				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	15.386	12.919	-	28.305
Value adjustment, biological assets	- 1.648	- 797	-	- 2.445
Production costs	- 13.688	- 10.224	-	- 23.912
Administrative costs	- 454	- 303	- 100	- 858
Other income	410	147	-	557
Other expense	188	-	-	188
Operating profit	195	1.741	100	1.836
Net Financials	- 307	- 330	- 899	- 1.536
Foreign exchange adjustments	-	5	246	251
Profit before tax	112	1.416	753	551
Tax on profit for the year	17	24	-	8
Profit for the period	95	1.392	753	543
EUR '000				
Depreciations included in production cost	- 732	- 1.098	-	- 1.830
EBITDA	927	2.840	100	3.667
<i>EBITDA fixed herd prices</i>	<i>2.575</i>	<i>3.637</i>	<i>100</i>	<i>6.111</i>

6M 2022				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	32.492	14.036	-	46.528
Value adjustment, biological assets	4.250	688	-	4.938
Production costs	- 30.807	- 14.913	-	- 45.720
Administrative costs	- 1.051	- 509	- 236	- 1.796
Other income	3.468	252	-	3.720
Other expense	12	-	-	12
Operating profit	8.365	446	236	7.683
Net Financials	- 559	- 455	- 847	- 1.861
Foreign exchange adjustments	-	109	- 319	- 210
Profit before tax	7.807	792	1.402	5.612
Tax on profit for the year	- 1.178	- 26	-	- 1.204
Profit for the period	6.628	818	1.402	4.408
EUR '000				
Depreciations included in production cost	- 1.313	- 1.938	-	- 3.251
EBITDA	9.678	1.492	236	10.934
<i>EBITDA fixed herd prices</i>	<i>5.428</i>	<i>804</i>	<i>236</i>	<i>5.996</i>
6M 2021				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	28.452	24.613	-	53.065
Value adjustment, biological assets	5.070	2.226	-	7.296
Production costs	- 27.230	- 21.028	-	- 48.258
Administrative costs	- 891	- 585	- 269	- 1.745
Other income	641	234	-	875
Other expense	322	-	-	322
Operating profit	6.363	5.460	269	11.555
Net Financials	- 604	- 662	- 1.917	- 3.184
Foreign exchange adjustments	-	34	500	466
Profit before tax	5.759	4.764	1.686	8.837
Tax on profit for the year	- 867	- 24	-	- 892
Profit for the period	4.891	4.740	1.686	7.945
EUR '000				
Depreciations included in production cost	- 1.483	- 2.120	-	- 3.602
EBITDA	7.846	7.580	269	15.157
<i>EBITDA fixed herd prices</i>	<i>2.776</i>	<i>5.354</i>	<i>269</i>	<i>7.861</i>

2021					
EUR '000	Lithuania	Russia	Other / Eliminations		Group
Revenue	53.864	46.298	-		100.163
Value adjustment, biological assets	159	112	-		271
Production costs	- 56.338	- 42.010	-		- 98.348
Administrative costs	- 1.808	- 1.287	- 626		- 3.721
Other income	2.818	6.865	-		9.683
Other expense	-	- 551	-		- 551
Operating profit	- 1.305	9.428	- 626		7.497
Net Financials	- 969	- 1.203	- 3.819		- 5.991
Foreign exchange adjustments	14	- 209	718		522
Profit before tax	- 2.260	8.016	- 3.728		2.029
Tax on profit for the year	492	107	-		385
Profit for the period	- 1.768	7.909	- 3.728		2.413
EUR '000					
Depreciations included in production cost	- 2.905	- 4.227	-		- 7.132
EBITDA	1.600	13.655	- 626		14.629
<i>EBITDA fixed herd prices</i>	<i>1.441</i>	<i>13.544</i>	<i>- 626</i>		<i>14.358</i>

Note 4 Summary of bond terms

Issuer	Idavang A/S
Security package:	(i) share pledges over Guarantors and Russian operating companies, (ii) mortgages over substantially Lithuanian real estate, (iii) Danish registered negative pledges, (iv) account pledge over IFC Deposit account and (v) assignment over intra-group loan (RUB 0.91bn) from the Issuer to Idavang Agro LLC
Original Guarantors:	Rus Invest Aps, Rurik A/S, Pskov Invest Aps, Idavang Russia A/S, UAB Idavang
Status of the bond:	Senior secured
Currency:	EUR
Initial debt amount:	EUR 75 millions
Other facilities:	Super senior RCF up to 9 mEUR, governed under an inter-creditor
Tenor	5 years
Pricing:	3m EURIBOR + 725 bps p.a., quarterly interest payments, EURIBOR floor of 0.0%
Rating:	Unrated
Call options:	Non call during the first 30 months, then 50/33/25/10/0 after 30/36/42/48/57
Incurrence test	Cash sweep of 50% of Free cash flow at 102.3925, starting from NIBD/EBITDA LTM fixed herd price (net leverage) of 3.00 and No
Restricted payments	No financial support (by way of loans, capital or similar) by the Issuer to Russian subsidiaries, except if funded by the super senior facility or if the incurrence test is met (excluding the IFC Deposit from Net Interest Bearing Debt)
Information covenants:	Annual audited statements, quarterly unaudited reports
Change of control:	Investor put at 101%
Listing of bonds:	Nasdaq Copenhagen
Trustee:	Nordic Trustee
Governing law:	Danish law

Quarterly Financial Highlights and Key Ratios

EUR '000	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q3 2021	Q2 2021
Income statement						
Revenue	25.957	20.571	20.394	26.703	26.703	28.305
EBITDA	3.486	7.448	- 3.165	2.637	2.637	3.667
EBITDA fixed herd price	5.733	263	- 1.039	7.536	7.536	6.111
EBIT	1.936	5.747	- 4.843	786	786	1.836
Financial items, net	- 449	- 1.622	- 1.212	- 1.539	- 1.539	- 1.285
Profit/(loss) for the period	901	3.507	- 5.486	- 46	- 46	543
Cash flow						
Operating activity	11.956	- 3.171	6.023	- 323	- 323	5.136
Investing activity	- 1.084	- 2.155	- 804	1.298	1.298	- 1.686
Financing activity	- 8.437	- 2.197	889	- 5.611	- 5.611	- 2.446
Free cash flow	11.059	- 3.652	6.130	2.640	2.640	4.735
Balance sheet						
Non-current assets	88.841	89.582	93.926	94.257	94.257	96.811
Net working capital	29.025	36.149	26.866	36.684	36.684	32.364
Net operating assets	117.866	125.732	120.792	130.941	130.941	129.175
Total assets	138.172	143.444	146.166	149.962	149.962	155.033
Equity	42.860	39.963	39.744	44.658	44.658	41.065
Net interest bearing debt	71.867	82.475	78.455	83.099	83.099	84.251
Key financials Group						
EBITDA margin	13,4%	36,2%	-15,5%	9,9%	9,9%	13,0%
EBITDA margin - fixed herd prices	22,1%	1,3%	-5,1%	28,2%	28,2%	21,6%
Cash conversion	192,9%	-1388,9%	-589,8%	35,0%	35,0%	77,5%
NIBD / EBITDA fixed price LTM	5,8	6,4	5,5	5,2	5,2	5,4
Equity ratio	31,0%	27,9%	27,2%	29,8%	29,8%	26,5%

Appendix / Production information

Idavang Group

	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Number of Sows average						
Lithuania	15.204	15.296	15.247	15.104	15.180	15.247
Russia	9.215	7.830	6.993	9.124	10.194	10.314
Total	24.419	23.126	22.240	24.228	25.374	25.561
Pigs sold (slaughterpigs, Weaners and Sows)						
Lithuania	121.517	118.165	123.861	119.534	119.392	119.931
Russia	52.284	53.960	57.190	80.074	87.681	89.239
Total	173.801	172.125	181.051	199.608	207.073	209.170
Displacement						
Lithuania	- 2.308	2.952	- 8.269	710	262	619
Russia	12.694	894	- 677	- 2.832	- 3.583	- 4.128
Total	10.386	3.846	- 8.946	- 2.122	- 3.321	- 3.509
Russia, Ostrov						
Total production						
Lithuania	119.209	121.117	115.592	120.244	119.654	120.550
Russia	64.978	54.854	56.513	77.242	84.098	85.111
Total	184.187	175.971	172.105	197.486	203.752	205.661
Feed cost kEUR						
Lithuania	- 11.420	- 9.375	- 9.487	- 10.136	- 9.326	- 8.798
Russia	- 5.475	- 4.742	- 5.686	- 6.911	- 6.882	- 7.123
Total	- 16.895	- 14.117	- 15.174	- 17.048	- 16.208	- 15.921
Feed conversion kg/kg						
Lithuania	2,78	2,86	2,86	2,88	2,81	2,79
Russia	2,86	2,84	2,90	2,89	2,82	2,99
Group	2,81	2,85	2,87	2,89	2,81	2,87

Appendix / Full segment balance Q2 2022

EUR '000	LT/DK	Russia	Group
Intangible assets	1.037	159	1.196
Property, Plant and Equipment	34.739	38.592	73.331
Biological Assets, Breeding herd	7.614	5.494	13.108
Deferred tax	761		761
Financial fixed assets	445		445
Total non-current assets	44.596	44.245	88.841
Inventories	2.934	8.538	11.472
Biological Assets, Commercial herd	13.657	5.767	19.423
Biological Assets, Arable	-	2.536	2.536
Biological Assets	13.657	8.303	21.959
Trade receivables	5.251	32	5.282
Other receivables	798	1.101	1.900
Prepayments	108	555	663
Income taxes receivables	390		390
Receivables	6.546	1.688	8.234
Cash	4.539	3.127	7.665
Total current assets	27.676	21.655	49.331
Total Assets	72.272	65.900	138.172

EUR '000	LT/DK	Russia	Group
Equity	-5.478	48.337	42.860
Borrowings	66.135		66.135
Grants	680	792	1.472
Deferred tax	1.666		1.666
Other non-current liabilities	654		654
Non current liabilities	69.135	792	69.927
Borrowings	1.092	12.306	13.398
Related parties	-1.978	1.978	
Trade payables	7.035	1.852	8.887
Income taxes payables	-	272	272
Other payables	2.466	362	2.828
Current liabilities	8.615	16.770	25.385
Total liabilities	77.750	17.562	95.312
Total Equity and Liabilities	72.272	65.900	138.172